Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canadian Paper Pushes Back On Biosimilar Switching

Brand-Backed Bodies’ Position Statement Expresses Caution

Executive Summary

A joint position statement published by originator-backed bodies the Canadian Association of Gastroenterology and Crohn’s and Colitis Canada has expressed caution over so-called ‘non-medical switching’ of IBD patients from brand biologics to biosimilars.

You may also be interested in...

Alberta Is Second Canadian Province To Switch To Biosimilars

Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

Brand-Backed Body Bemoans British Columbia’s Biosimilars Boost

A body supported by biologic originators has attacked British Columbia’s move to switch Crohn’s and colitis patient to infliximab biosimilars, even though the resulting savings will be invested in patient care.

Canadian Province Expands Biosimilar Switching, But Patient Group Voices Concerns

British Columbia’s move to switch gastrointestinal patients to biosimilar infliximabs by March 2020 has pleased local industry but upset an originator-backed patients’ group.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts